📈   Jasper shares rally as chronic hives drug scores in small, early trial

tech

Jasper Therapeutics’ anti-c-KIT antibody has shown promise in a Phase 1b/2a test in people with certain irritable skin conditions, sending its shares rising on Monday. Fourteen out of 15 participants in the SPOTLIGHT study with cold urticaria or symptomatic dermographism who are refractory to antihistamines had a clinical response to briquilimab within the six-week preliminary analysis period, according to a Monday release. Cold urticaria and symptomatic dermographism both lead to hives and swelling but are caused by different triggers. Cold urticaria is due to cold temperatures, while symptomatic dermographism is provoked by rubbing or scratching of the skin. Jasper’s shares $JSPR rose by as much as 20% at market open Monday.

Endpoints     Oct 14, 2024